• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Pyxis Oncology, Inc. - Common Stock (NQ:PYXS)

    1.383 -0.037 (-2.61%)
    Streaming Delayed Price Updated: 10:51 AM EST, Jan 8, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 241,580
    Open 1.440
    Bid (Size) 1.380 (900)
    Ask (Size) 1.390 (2,200)
    Prev. Close 1.420
    Today's Range 1.350 - 1.440
    52wk Range 0.8332 - 5.550
    Shares Outstanding 38,245,287
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Unusual volume stocks in Tuesday's session ↗
    Let's explore the current happenings on the US markets on Tuesday. Below, you'll find the stocks exhibiting unusual volume in today's session. 
    Via Chartmill
    News headline image
    Top movers in Thursday's session ↗
    Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report. 
    Via Chartmill

    Performance

    YTD
    +20.3%
    +20.3%
    1 Month
    -66.9%
    -66.9%
    3 Month
    -52.5%
    -52.5%
    6 Month
    +18.2%
    +18.2%
    1 Year
    -20.5%
    -20.5%

    More News

    Read More
    News headline image
    Keep an eye on the top gainers and losers in Thursday's session. ↗
    Via Chartmill
    News headline image
    There are notable gap-ups and gap-downs in today's session. ↗
    Via Chartmill
    News headline image
    Discover the top movers in Thursday's pre-market session. ↗
    Via Chartmill
    News headline image
    Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
    From Pyxis Oncology
    Via GlobeNewswire
    News headline image
    Pyxis Oncology to Participate in Upcoming Investor Conferences
    From Pyxis Oncology
    Via GlobeNewswire
    News headline image
    Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results
    From Pyxis Oncology
    Via GlobeNewswire
    News headline image
    Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings
    From Pyxis Oncology
    Via GlobeNewswire
    News headline image
    Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets
    From Pyxis Oncology
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Monday's After-Market Session ↗
    Via Benzinga
    News headline image
    Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Pyxis Oncology
    Via GlobeNewswire
    News headline image
    Pyxis Oncology to Participate in September Investor and Industry Conferences
    From Pyxis Oncology
    Via GlobeNewswire
    News headline image
    Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
    From Pyxis Oncology
    Via GlobeNewswire
    News headline image
    Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Pyxis Oncology
    Via GlobeNewswire
    News headline image
    Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update
    From Pyxis Oncology
    Via GlobeNewswire
    News headline image
    Pyxis Oncology to Participate in Two Upcoming Investor Conferences
    From Pyxis Oncology
    Via GlobeNewswire
    News headline image
    Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC
    From Pyxis Oncology
    Via GlobeNewswire
    News headline image
    Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
    From Pyxis Oncology
    Via GlobeNewswire
    News headline image
    Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025
    From Pyxis Oncology
    Via GlobeNewswire
    News headline image
    Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
    From Pyxis Oncology
    Via GlobeNewswire
    News headline image
    Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference
    From Pyxis Oncology
    Via GlobeNewswire
    News headline image
    Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
    From Pyxis Oncology
    Via GlobeNewswire
    News headline image
    Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial
    From Pyxis Oncology
    Via GlobeNewswire
    News headline image
    Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move ↗
    Via Benzinga

    Frequently Asked Questions

    Is Pyxis Oncology, Inc. - Common Stock publicly traded?
    Yes, Pyxis Oncology, Inc. - Common Stock is publicly traded.
    What exchange does Pyxis Oncology, Inc. - Common Stock trade on?
    Pyxis Oncology, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Pyxis Oncology, Inc. - Common Stock?
    The ticker symbol for Pyxis Oncology, Inc. - Common Stock is PYXS on the Nasdaq Stock Market
    What is the current price of Pyxis Oncology, Inc. - Common Stock?
    The current price of Pyxis Oncology, Inc. - Common Stock is 1.383
    When was Pyxis Oncology, Inc. - Common Stock last traded?
    The last trade of Pyxis Oncology, Inc. - Common Stock was at 01/08/26 10:51 AM ET
    What is the market capitalization of Pyxis Oncology, Inc. - Common Stock?
    The market capitalization of Pyxis Oncology, Inc. - Common Stock is 52.89M
    How many shares of Pyxis Oncology, Inc. - Common Stock are outstanding?
    Pyxis Oncology, Inc. - Common Stock has 53M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.